Led · Equity · Feb 2020

NeuroVasc Technologies develops catheter-based technologies and a portfolio of devices to treat neurovascular disease, including a next-generation mechanical thrombectomy system and a novel stent-retriever. The company’s core thrombectomy system is designed to improve clot retrieval in tortuous anatomy and has received a CE Mark. NeuroVasc is commercially active in Europe and Hong Kong and planned 2020 commercial expansion into South America and Southeast Asia. The company has assembled an internal and acquired catalogue of products aimed at addressing unmet needs in neurovascular treatment. In 2015 the company was founded and is privately held and based in Irvine, Calif. It has announced a strategic partnership with Wego Group that includes $34 million to support product development and global clinical trials, and the company says this partnership is accelerating its growth. NeuroVasc Technologies is a medical device company focused on developing devices to treat neurovascular conditions. The company holds CE mark for the Versi Mechanical Thrombectomy System, which is used to remove clots from the blood vessels of the brain during an acute ischemic stroke. The Versi system is not yet cleared by the FDA for use in the USA. NeuroVasc intends to use proceeds from the financing to expand its development efforts. Founded in 2015 by Jim Ma (CEO) and based in Laguna Hills, CA, the company completed a $6.3M Series B financing. The round was led by ShangBay Capital with participation from other investors.

Led · Equity · Feb 2020

NeuroVasc Technologies, founded in 2015 and based in Los Angeles, develops catheter-based technologies to treat neurovascular disease. Its core product is a next-generation mechanical thrombectomy system (a novel stent-retriever) designed to improve clot retrieval in tortuous anatomy. The company is pursuing a portfolio strategy that combines internally developed and acquired devices to address unmet needs in stroke care. NeuroVasc closed $34M in funding via a strategic partnership with Wego Group to support product portfolio development and a global clinical trial program. Initial proceeds have been applied to clinical trials for its stent-retriever across major markets including Japan, the EU, the US, and China. The company positions its pipeline against a global stroke burden of over 25.7 million cases annually and a neurovascular devices market projected to grow from $2.5B to $3.4B by 2025, and aims to bring a full neurovascular platform to market.